Bausch Health Companies vs Grifols
BHC and GRFS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and GRFS compare
Bausch Health Companies grew revenue faster over the last twelve months (10.8% versus 4.3% for Grifols).
Grifols keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with −7.6% at Bausch Health Companies.
Grifols scores higher on the StockData Score (9 against 8 for Bausch Health Companies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | GRFS |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | – |
| Share price | $8.35 | $8.69 |
| Change, 1 year | 20.3% | 0.00% |
| Change, 5 years | −67.9% | −26.9% |
| Beta (5Y) | 1.00 | 0.89 |
| Employees | 20K | 1,613 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× | – |
| EV/EBITDA | 9.3× | – |
| P/FCF | 1.7× | – |
| FCF yield | 59.7% | – |
| Fair value | $37.02 | – |
| Margin of safety | 77.4% | – |
| Growth | ||
| Revenue growth (TTM) | 10.8% (better) | 4.3% |
| Revenue growth, 5Y average | 5.0% | 7.1% (better) |
| Net income growth (TTM) | −332% | 156% (better) |
| EPS growth (TTM) | −336% | 157% (better) |
| EPS growth, 5Y average | – | −8.1% |
| Profitability | ||
| Gross margin | – | 38.0% |
| Operating margin | 11.2% | 16.5% (better) |
| Net margin | −7.6% | 5.3% (better) |
| FCF margin | 16.8% (better) | 10.4% |
| Return on equity | – | 7.2% |
| Return on invested capital | 5.5% | 14.6% (better) |
| Financial health | ||
| Debt / equity | – | 0.41 |
| Net debt / EBITDA | 7.57 | 0.79 (better) |
| Interest coverage | 0.8× | 2.0× (better) |
| Current ratio | 1.56 | 2.51 (better) |
| Altman Z-score | 0.22 | – |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Payout ratio | – | 31.8% |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 63.4% | 20.8% |
| Held by insiders | 31.5% | 0.00% |
| Insider net buying, 12 months | −$507K | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.9% | – |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.